Which statement best describes the use of vaptans?

Which statement best describes the use of vaptans?

• A. They are safe for outpatient use in euvolemic hyponatremia
• B. They are never approved for hyponatremia
• C. They are used in hospital for euvolemic or hypervolemic hyponatremia
• D. They have proven mortality benefit

Answer: (C)

Vaptans block vasopressin’s action at the V2 receptors in the collecting ducts, which promotes free water excretion (aquaresis) without losing solutes. This helps raise serum sodium in hyponatremia driven by excess water, especially in euvolemic states like SIADH and in hypervolemic conditions such as heart failure or cirrhosis. Because correcting sodium too quickly can cause serious brain injury, these drugs are used in hospital settings with careful monitoring of sodium levels and fluid status. They are not universally approved for outpatient use due to safety concerns, including the risk of rapid overcorrection and, for some agents, potential liver toxicity. Importantly, vaptans can correct sodium but have not shown a mortality benefit in major trials. Thus, their appropriate setting is in-hospital treatment for euvolemic or hypervolemic hyponatremia.

Vaptans block vasopressin’s action at the V2 receptors in the collecting ducts, which promotes free water excretion (aquaresis) without losing solutes. This helps raise serum sodium in hyponatremia driven by excess water, especially in euvolemic states like SIADH and in hypervolemic conditions such as heart failure or cirrhosis. Because correcting sodium too quickly can cause serious brain injury, these drugs are used in hospital settings with careful monitoring of sodium levels and fluid status. They are not universally approved for outpatient use due to safety concerns, including the risk of rapid overcorrection and, for some agents, potential liver toxicity. Importantly, vaptans can correct sodium but have not shown a mortality benefit in major trials. Thus, their appropriate setting is in-hospital treatment for euvolemic or hypervolemic hyponatremia.